Professor Matthew Cramp
Profiles

Professor Matthew Cramp

Chair in Hepatology

Peninsula Medical School (Faculty of Health)

Key publications are highlighted

Journals
Articles
Sánchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L & Heward J 2020 'Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation' American Journal of Transplantation , DOI
Alsaleh M, Leftley Z, Barbera TA, Koomson LK, Zabron A, Crossey MME, Reeves HL, Cramp M, Ryder S & Greer S 2020 'Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort' Journal of Clinical and Experimental Hepatology 10, (1) 17-29 , DOI
Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, Baker A, Batterham R, Brown K & Burton R 2020 'Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK' The Lancet 395, (10219) 226-239 , DOI
Dhanda AD, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ & Cramp ME 2019 'Ex Vivo T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis' Gut and Liver , DOI PEARL
Dhanda AD, Williams EL, Yates E, Lait PJP, Schewitz-Bowers LP, Hegazy D, Cramp ME, Collins PL & Lee RWJ 2019 'Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4+ T Cells' The Journal of Immunology ji1800742-ji1800742 , DOI
Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M & Rodriguez CF 2019 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis' Journal of Hepatology 71, (4) 660-665 , DOI
Norton BC, Srivastava A, Ramos K, Vine L, Taylor R, Aluvihare V, Heaton N & Cramp ME 2019 'Risk-adjusted survival in liver transplant patients assessed and managed by a non-transplanting centre: South West Liver Unit experience' Frontline Gastroenterology , DOI
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K & Lahser F 2019 'Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6' Journal of Viral Hepatitis , DOI
Bennett K, Enki DG, Thursz M, Cramp ME & Dhanda AD 2019 'Systematic review with meta-analysis: high mortality in patients with nonsevere alcoholic hepatitis' Alimentary Pharmacology and Therapeutics , DOI PEARL
Vergara C, Thio CL, Johnson E, Kral AH, O’Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH & Kirk GD 2019 'Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' Gastroenterology 156, (5) 1496-1507.e7 , DOI
Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R & Cramp ME 2018 'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 392, (10162) 2398-2412 , DOI
Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA & Jones DEJ 2018 'Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom' Alimentary Pharmacology & Therapeutics 48, (9) 951-960 , DOI
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F & Cardinale V 2018 'Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score' The Lancet Gastroenterology & Hepatology 3, (9) 626-634 , DOI
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 2018 'Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial' Hepatology 67, (6) 2113-2126 , DOI
Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N & Dhawan A 2017 'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 391, (10125) 1097-1107 , DOI
Ow MM, Hegazy D, Warshow UM & Cramp ME 2017 'Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood' Journal of Viral Hepatitis 25, (3) 245-253 , DOI PEARL
Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S & Aneja J 2017 'Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection' Scientific Reports 7, Author Site , DOI PEARL
Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME 2017 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 , DOI PEARL
Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME 2017 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis , DOI PEARL
Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, Roudot-Thoraval F, Craxi A, Manns M & Marinho RT 2017 'Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study' The Lancet Gastroenterology & Hepatology 2, (5) 325-336 , DOI
Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A, Dillon J & Dyson J 2017 'New metrics for the Lancet Standing Commission on Liver Disease in the UK' The Lancet 389, (10083) 2053-2080 , DOI
Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, Waked I, Alavian SM, Lee M-H & Negro F 2017 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study' The Lancet Gastroenterology & Hepatology 2, (3) 161-176 , DOI
Dhanda AD, Sinha A, Hunt V, Saleem S, Cramp ME & Collins PL 2017 'Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids' World Journal of Gastroenterology 23, (11) 2052-2052 , DOI PEARL
Acevedo JG & Cramp ME 2017 'Hepatorenal syndrome: Update on diagnosis and therapy' World Journal of Hepatology 9, (6) 293-293 , DOI PEARL
Shariff MIF, Kim JU, Ladep NG, Crossey MME, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S & Greer S 2016 'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy' Journal of Clinical and Experimental Hepatology 6, (3) 186-194 , DOI
Swann RE, Mandalou P, Robinson MW, Ow MM, Foung SKH, McLauchlan J, Patel AH & Cramp ME 2016 'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection' Journal of Viral Hepatitis 23, (11) 873-880 , DOI PEARL
Vine LJ, Sieberhagen C & Cramp ME 2015 'Diagnosis and management of hepatitis C' British Journal of Hospital Medicine 76, (11) 625-630 , DOI
Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J & Dyson J 2015 'Implementation of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 386, (10008) 2098-2111 , DOI
Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P & Williamson K 2015 'The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis' Hepatology 63, (3) 930-950 , DOI
Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D & Qian DC 2015 'International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways' Nature Communications 6, (1) , DOI PEARL
Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG & Cramp ME 2015 'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV' J Med Virol 87, (7) 1207-1217 Author Site , DOI
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H & Clements A 2015 'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact' JOURNAL OF VIRAL HEPATITIS 22, (4) 399-408 Author Site , DOI PEARL
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G & Gilmore I 2014 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 Author Site
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G & Gilmore I 2014 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 Author Site , DOI
Ow MMG, Erasmus P, Minto G, Struthers R, Joseph M, Smith A, Warshow UM, Cramp ME & Cross TJS 2014 'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation' Liver Transpl 20, (9) 1081-1088 Author Site , DOI
Jothimani D, Cramp ME & Cross TJS 2014 'Role of Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis—An Observational Study' Journal of Clinical and Experimental Hepatology 4, (3) 221-225 , DOI
Cramp ME, Rosenberg WM, Ryder SD, Blach S & Parkes J 2014 'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality' BMC Gastroenterol 14, Author Site , DOI PEARL
Bruggmann P, Berg T, Øvrehus ALH, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD & Sperl J 2014 'Historical epidemiology of hepatitis C virus (HCV) in selected countries' J Viral Hepat 21 Suppl 1, 5-33 Author Site , DOI
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M & Akarca U 2014 'Strategies to manage hepatitis C virus (HCV) disease burden' J Viral Hepat 21 Suppl 1, 60-89 Author Site , DOI
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C & Lázaro P 2014 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm' J Viral Hepat 21 Suppl 1, 34-59 Author Site , DOI
Houldsworth A, Metzner M, Shaw S, Kaminski E, Demaine AG & Cramp ME 2014 'Polymorphic differences in SOD-2 may influence HCV viral clearance' J Med Virol 86, (6) 941-947 Author Site , DOI
Houldsworth A, Metzner MM, Demaine A, Hodgkinson A, Kaminski E & Cramp M 2014 'CD81 sequence and susceptibility to hepatitis C infection' JOURNAL OF MEDICAL VIROLOGY 86, (1) 162-168 Author Site , DOI
Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, Hydes TJ, Cramp ME, Alexander G & Little A-M 2013 'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection' Hepatology 58, (3) 881-889 Author Site , DOI
Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT & Peters MG 2013 'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts' Ann Intern Med 158, (4) 235-245 Author Site , DOI
Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S & Cramp ME 2012 'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection' J Viral Hepat 19, (7) 501-508 Author Site , DOI
Saunders M, Sieberhagen C, Taylor L, Fry F, McKenna M, Needs S, Chimakurthi R & Cramp M 2012 'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION' GUT 61, A140-A141 Author Site , DOI
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2012 'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis' Eur J Gastroenterol Hepatol 24, (5) 543-550 Author Site , DOI
Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI 2011 'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection' Gut 60, (Suppl 2) A51-A52 , DOI
Warshow U, Sieberhagen C, Hegazy D, Kaminski E, Knapp S, Khakoo S & Cramp ME 2011 'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection' Gut 60, (Suppl 2) A21-A22 , DOI
Petrova M, Fung M, Cramp ME, Mitchell JD & Cross TJS 2011 'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience' Gut 60, (Suppl 2) A37-A37 , DOI
Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, Alexander G, Thursz M, Cramp M & Khakoo SI 2011 'A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection' GASTROENTEROLOGY 141, (1) 320-U419 Author Site , DOI
Jothimani D, Cramp ME, Mitchell JD & Cross TJS 2011 'Treatment of autoimmune hepatitis: a review of current and evolving therapies' J Gastroenterol Hepatol 26, (4) 619-627 Author Site , DOI
Thurairajah PH, Hegazy D, Demaine A, Kaminski ER & Cramp ME 2011 'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation' J Infect Dis 203, (6) 847-853 Author Site , DOI
Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little A-M, Alexander GJ, Rosenberg WMC & Cramp ME 2010 'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus' HEPATOLOGY 51, (4) 1168-1175 Author Site , DOI
Rashid M, Mitchell JD, Cramp ME & Cross TJS 2010 'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C' HEPATOLOGY 51, (1) 354-355 Author Site , DOI
Cross TJS, Mitchell JD & Cramp ME 2009 'Elastography for the non-invasive assessment of liver disease: limitations and future developments' GUT 58, (8) 1171-1172 Author Site
Marcellin P, Reesink H, Berg T, Cramp M, Flisiak R, Van Vlierberghe H, Verloes R, Lenz O, Peeters M & Sekar V 2009 'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY' JOURNAL OF HEPATOLOGY 50, S385-S385 Author Site , DOI
Hegazy D, Thurairajah P, Metzner M, Houldsworth A, Shaw S, Kaminski E, Demaine AG & Cramp ME 2008 'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection' Clin Exp Immunol 152, (3) 538-541 Author Site , DOI
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M & Stein K 2008 'Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis' British Journal of Cancer 98, (7) 1166-1175 , DOI PEARL
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K 2007 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technol Assess 11, (34) 1-206 Author Site , DOI
Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K 2007 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technology Assessment 11, (34) 1-+
Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U & Stein K 2006 'Case finding for hepatitis C in primary care: a cost utility analysis' Fam Pract 23, (4) 393-406 Author Site , DOI
Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C & Cramp ME 2006 'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression' Int J STD AIDS 17, (1) 67-69 Author Site , DOI
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K 2006 'The cost-effectiveness of testing for hepatitis C in former injecting drug users' Health Technology Assessment 10, (32) 1-+
Awasthi AK & Cramp ME 2005 'Hepatic hydrothorax' Br J Hosp Med (Lond) 66, (9) 540-541 Author Site , DOI
Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG & Cramp ME 2005 'Polymorphisms in the IL-12B gene and outcome of HCV infection' J Interferon Cytokine Res 25, (5) 271-276 Author Site , DOI
Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Dalton HR, Harrison TJ, Hill SF & MacFarlane L 2005 'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics' Journal of Infectious Diseases 192, (7) 1166-1172
Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D & Hilgartner M 2004 'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection' Science 305, (5685) 872-874 Author Site , DOI
Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, Williams R & Naoumov NV 2004 'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity' J Med Virol 72, (3) 370-376 Author Site , DOI
Horne JA, Clements AJ, Drennan P, Stein K & Cramp ME 2004 'Screening for hepatitis C virus in the Dartmoor prison population: an observational study' Journal of Public Health 26, (4) 372-375
Kyrlagkitsis L, Portmann B, Smith H, O'Grady J & Cramp ME 2003 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' AMERICAN JOURNAL OF GASTROENTEROLOGY 98, (7) 1588-1593 Author Site , DOI
Kyrlagkitsis I, Portmann B, Smith H, O'Grady J & Cramp ME 2003 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' Am J Gastroenterol 98, (7) 1588-1593 Author Site , DOI
Metzner M, Maulayah P, Benshemesh C & Cramp ME 2003 'Traditional Chinese medicine in the treatment of chronic HCV infection' Gut 52, (5)
Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, McFarlane IG, Cramp ME & Donaldson PT 2002 'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy' Liver 22, (5) 404-412 Author Site , DOI
Saravanan R & Cramp ME 2002 'Investigation and treatment of ascites' Clin Med (Lond) 2, (4) 310-313 Author Site , DOI
Katona SJ, Cooper PC, Cramp ME & Kaminski ER 2002 'Re: Whither smooth muscle antibodies in the third millennium?' J Clin Pathol 55, (7) 558-559 Author Site , DOI
Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA & Cramp ME 2002 'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases' J Hepatol 36, (2) 295-301 Author Site , DOI
Kyrlagkitsis I, Cramp ME, Smith H, Portmann B & O'Grady J 2002 'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center' Hepatogastroenterology 49, (44) 524-528 Author Site
Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O'Grady J & Rela M 2001 'Liver transplantation in adults coinfected with HIV' Transplantation 72, (10) 1684-1688 Author Site , DOI
Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O???Grady J & Rela M 2001 'Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684' Transplantation 72, (10) 1594-1595 , DOI
Kyrlagkitsis I, Portmann B & Cramp ME 2000 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT' HEPATOLOGY 32, (4) 285A-285A Author Site
Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MH 2000 'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)' J Am Acad Dermatol 43, (2 Pt 2) 403-408 Author Site , DOI
Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MHA 2000 'Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)' Journal of the American Academy of Dermatology 43, (2) 403-408 , DOI
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 2000 'Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C' Gastroenterology 118, (2) 346-355 , DOI
Cramp ME 1999 'HBV + HCV = HCC?' Gut 45, (2) 168-169 Author Site , DOI
Cramp ME 1999 'HBV plus HCV=HCC?' GUT 45, (2) 168-169 Author Site , DOI
Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F & Vogel W 1999 'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre' Gut 44, (4) 563-567 Author Site , DOI
Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R & Naoumov NV 1999 'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia' Gut 44, (3) 424-429 Author Site , DOI
Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R & Donaldson PT 1998 'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia' J Hepatol 29, (2) 207-213 Author Site , DOI
CRAMP ME & WILLIAMS R 1997 'Hepatitis in alcohol and drug misusers: practical issues' Addiction Biology 2, (4) 411-420 , DOI
Cramp ME, Grundy HC, Perinpanayagam RM & Barnado DE 1996 'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults' J R Soc Med 89, (7) 401-402 Author Site
Cramp ME, Hing MC, Marriott DJ, Freund J & Cooper DA 1996 'Bile acid malabsorption in HIV infected patients with chronic diarrhoea' Aust N Z J Med 26, (3) 368-371 Author Site , DOI
Inwald D, Nelson M, Cramp M, Francis N & Gazzard B 1994 'Cutaneous manifestations of mycobacterial infection in patients with AIDS' Br J Dermatol 130, (1) 111-114 Author Site , DOI
Cramp ME, Hickey MM & Gazzard MM 1993 'Re-emergence of tuberculosis' BMJ 306, (6882) Author Site , DOI
Grange JM & Yates MD 1993 'Re-emergence of tuberculosis' BMJ 306, (6882) 931-932 , DOI
Collins CD, Blanshard C, Cramp M, Gazzard B & Gleeson JA 1992 'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection' Clin Radiol 46, (6) 410-411 Author Site , DOI
Tattersall JE, Cramp M, Shannon M, Farrington K & Greenwood RN 1992 'Rapid high-flux dialysis can cure uraemic peripheral neuropathy' Nephrol Dial Transplant 7, (6) 539-540 Author Site
Chapters
Cyril S & Cramp ME 2013 'Clinical and Pathological Features, and Diagnosis' Viral Hepatitis John Wiley & Sons, Ltd 442-449 , DOI
Palmer DH & Cramp ME 2011 'Systemic Therapy for Hepatocellular Carcinoma: Future Directions' Clinical Dilemmas in Primary Liver Cancer Wiley-Blackwell 199-211 , DOI
Conference Papers
Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, Subramanian M & Myers RP 2018 'Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial' 8A-9A
Haber B, Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD & Ustianowski A 2017 'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study' Elsevier BV S1061-S1061 , DOI
Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 2016 'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks' 39A-40A
Agarwal K, Schultz M, Pianko S, Bank L, Collier J, George J, Priest M, Ryder SD, Burman BE & Cheent K 2016 'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin' 455A-456A
Ahmed A, Dhanda A, Hegazy D, Felmlee D, Sheridan D & Cramp M 2016 'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype' 745A-745A
Jothimani D, Govil S, Vij M, Sheridan D, Cramp M & Rela M 2016 'Predicting Fatty Liver Disease in Healthy Potential Liver Donors' Elsevier BV S479-S479 , DOI
Asselah T, Shafran S, Bourgeois S, Lai C-L, Cramp M, Mathurin P, Willems B, Nguyen MH, Davis MN & Huang KC 2016 'SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)' S827-S828
Mandalou P, Robinson MW, Felmlee D, Sieberhagen C, Mindos T, Hegazy D, MacLaughlan J & Cramp ME 2015 'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv' BMJ A452.1-A452 , DOI
Norton BC, Adebayo D, Ramos K, Smith A & Cramp M 2015 'PTH-124 Liver transplant outcomes in patients with care devolved to a non-transplanting centre: south west liver unit experience' BMJ A462.2-A463 , DOI
Dhar A, Tschotazis E, Brown R, Manousou P, Millson C, Aldersley M, Forbes S, Aggarwal K, Gera A & Cramp M 2015 'LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year' Elsevier BV S268-S269 , DOI
Ow M, Hegazy D & Cramp ME 2014 'P210 ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY' Elsevier BV S136-S136 , DOI
Rosenberg WM, Cramp M, Davis M, Parkes J, Ryder S, Razavi H & Hindman S 2014 'P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND' Elsevier BV S333-S334 , DOI
Ow MM, Hegazy D, Warshow U & Cramp ME 2014 'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity' 1064A-1064A
Mandalou P, Swann R, Patel AH & Cramp ME 2014 'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV' 1057A-1057A
Martin NK, Vickerman P, Clements A, Cramp M, De Angeles D, Dillon JF, Fahey S, Foster GR, Goldberg DJ & Gordon F 2013 'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS' S356-S356 , DOI
Joseph M, Erasmus P, Minto G, Mitchell J, Cramp M & Cross TJ 2013 'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES' S412-S412 , DOI
Petrova M, Fung M & Cramp M 2012 'HPS AND INTRAPULMONARY VASCULAR SHUNTS IN LIVER TRANSPLANT CANDIDATES' S254-S254 , DOI
Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI 2011 'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection' 173-173
Warshow U, Sieberhagen C, Hegazy DM, Kaminski E, Knapp S, Khakoo S & Cramp ME 2011 'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION' 1322A-1322A
Knapp S, Ho KM, Warshow U, Heqazy D, Little A-M, Alexander G, Thursz M, Cramp ME & Khakoo SI 2011 'ABSENCE OF IL-28B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION' S38-S39 , DOI
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2010 'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE' 710A-711A
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM 2010 'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION' 710A-710A
Sieberhagen C, Brown ASM, Demuth DG, Livingstone JA & Cramp ME 2010 'PTU-069 Predictors of hepatitis C treatment outcome in genotype 1 patients in a “real world” setting' BMJ A77.1-A77 , DOI
Warshow U, Knapp S, Brackenbury LS, Hegazy D, Thurairajah PH, Khakoo S & Cramp ME 2009 'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION' 386A-386A
Hegazy D, Edwards P, Warshow U & Cramp ME 2009 'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES' 950A-950A
Warshow U, Riva A, Thurairajah PH, Hegazy D, Chokshi S & Cramp ME 2009 'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION' 936A-936A
Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME 2009 'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' A17-A17
Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME 2009 'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' S326-S326 , DOI
Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV & Cramp ME 2008 'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection' United States 1749-1755 , DOI
Barnardo AT, Walters L, Cramp M & Mitchell J 2008 'Audit of management of alcohol withdrawal at derriford hospital' A72-A72
Barnardo AT, Warshow U, Mitchell J & Cramp M 2008 'Mycophenolate mofetil in patients with refractory autoimmune hepatitis' A71-A72
Thurairajah PH, Hegazy DM, Richardon SJ, Demaine AG, Kaminski ER & Cramp ME 2007 'HCV-specific cellular immune responses in intravenous drug users without HCV infection' 240A-241A
Hegazy DM, Thurairajah PH, Metzner M, Houldsworth A, Kaminski E, Demaine A & Cramp ME 2007 'Interleukin 12B gene polymorphism and apparent resistance to HCV infection' 890A-891A
Thurairajah PH, Hegazy D, Kaminski E, Demaine A & Cramp ME 2007 'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection' A134-A135
Thurairajah PH, Hegazy D, Kaminski E, Demaine A, Cunningham R & Cramp ME 2006 'Late spontaneous clearance of hepatitis C' A43-A43
Houldsworth A, Metzner MM, Demaine A, Hodgkinson A, Kaminski E & Cramp M 2005 'CD81 sequence and susceptibility to hepatitis C infection' Wiley 162-168 , DOI
Metzner M, Houldsworth A, Demaine AG, Kaminski E & Cramp ME 2005 'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV' A6-A7
Metzner MK, Houldsworth A, Demaine A, Kaminski E & Cramp ME 2005 'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV' A712-A712 PEARL
Beckly JB, Jackson S, Cramp ME & Beckly DE 2004 'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks' A44-A44
Houldsworth A, Metzner M, Rossol S, Kaminski E, Demaine AG & Cramp ME 2003 'IL-12 gene polymorphism and outcome of HCV infection' 356A-356A
Kyrlagkitsis I, Metzner M, Smith H, Depla E, Sablon E & Cramp ME 2003 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
Kyrlagkitsis I, Metzner MK, Smith H, Depla E, Sablon E & Cramp ME 2002 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA' 552A-552A
Metzner MK, Maulayah P, Benshemesh C & Cramp ME 2002 'Traditional Chinese medicine in the treatment of chronic HCV infection' 569A-569A
Clark SJ, Creighton S, Horner M, Portmann BC, Cramp M & Taylor C 2000 'Reactivation of latent hepatitis B virus infection with HIV related immunosuppression' 454A-454A
Clare MA, Portmann BC & Cramp ME 1999 'The association of the Arg25Pro polymorphism in the TGF beta 1 gene with fibrosis in chronic hepatitis C patients' 331A-331A
Cramp ME, Maertens G, O'Grady J & Rossol S 1999 'HCV-specific immune responses in HCV exposed but uninfected cases' A97-A97
Cramp ME & Rossol S 1998 'HCV-specific T helper cell responses in HCV exposed but uninfected cases' 200A-200A
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1998 'HLA class III and class II alleles in hepatitis C virus infection and outcome' 159-160
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1998 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 155-155
Torre F, Cramp M, Owsianka A, Carman W, Williams R & Naoumov NV 1998 'Mutations within a promiscuous immunodominant epitope in hepatitis B core protein and their effect on T helper cell response' 156-157
Cramp ME, Rossol S, Carucci P, Williams R, Naoumov NV & Donaldson PT 1998 'The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses' A21-A21
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV 1997 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 1111-1111
Rossol S, Cramp ME, Carucci P, Singer MV, Williams R & Naoumov NV 1997 'Reduced production of interleukin-12 by PBMC from patients with chronic hepatitis C' 1121-1121
Torre F, Cramp ME, Owsianka A, Carman W, Williams R & Naoumov NV 1997 'T helper cell response to mutations within a promiscuous immunodominant epitope in acute and chronic hepatitis B' 1953-1953
Bernal W, Cramp M, Underhill JA, Carucci P & Donaldson PT 1997 'Tumor necrosis factor gene polymorphisms in hepatitis C virus infection' 1413-1413
Cramp ME, Chokshi S, Tzampouras N, Torre F, Williams R & Naoumov NV 1997 'Beneficial in vitro effects of tucaresol on the immune response to hepatitis C virus' TH119-TH119
Cramp ME, Carucci P, Chokshi S, Rossol S, Donaldson PT, Williams R & Naoumov NV 1996 'A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure' 503-503
Cramp ME, Carucci P, Donaldson PT, Underhill J, Tibbs C, Naoumov NV & Williams R 1996 'Evidence that HLA class II genotype may be associated with clearance of hepatitis C virus' 99-99
Reports
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K 2006 The cost-effectiveness of testing for hepatitis C in former injecting drug users. Author Site , DOI
Posters
Yates E, Cramp M & Dhanda A Yates E, Cramp M & Dhanda A 0 'A NOVEL FUNCTIONAL BIOASSAY PREDICTS 90-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS' 0 0 Author Site , DOI PEARL
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 0 'Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study' 0 0 , DOI
Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M 0 'Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16−) monocytes' 0 0 , DOI
Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 0 'Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment' 0 0 , DOI